Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Henlius and Sandoz Strike Strategic Biosimilars Deal Covering Up to 10 mAb and ADC Products Worth USD 314 Million for Initial Assets

Fineline Cube Aug 17, 2026
Company Deals

Xbiome Strikes NewCo‑Style Technology Collaboration with Biogent Therapeutics for AI‑Driven Bispecific Antibody Development

Fineline Cube Aug 14, 2026
Company Deals

ACROBiosystems and Bailinke Pharmaceutical Form Strategic Partnership to Build AI‑Empowered Affinity Purification Solutions

Fineline Cube Aug 14, 2026
Company Deals

IASO Biotherapeutics Completes Acquisition of MediSix Therapeutics – Adding PEBL‑Based CAR‑T Cell Therapy Platform for T‑Cell Malignancies

Fineline Cube Aug 14, 2026
Company Deals

Hybio Pharmaceutical Grants Wansheng Pharmaceutical Exclusive China License for Semaglutide’s Glycemic Control Indication in Up-to-RMB 182.5 Million Deal

Fineline Cube Aug 13, 2026
Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Fineline Cube Aug 17, 2026
Company Drug

AstraZeneca Launches Tezspire in China, Bringing First‑In‑Class TSLP Inhibitor Tezepelumab to Severe Asthma and CRSwNP Patients

Fineline Cube Aug 17, 2026
Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Fineline Cube Aug 17, 2026
Company Drug

Atom Bioscience Initiates Global Phase III Clinical Study for Gout Drug ABP-671

Fineline Cube Oct 10, 2023

China-based Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd) has announced the enrollment of...

Policy / Regulatory

China’s National Health Commission Launches Three-Year Patient Safety Campaign

Fineline Cube Oct 10, 2023

The National Health Commission has issued a notification to launch a special patient safety campaign...

Company Drug

GluBio Pharmaceutical’s GLB-002 Receives NMPA Approval for Clinical Trials in Hematological Tumors

Fineline Cube Oct 10, 2023

GluBio Pharmaceutical Co., Ltd, a specialist in molecular glue targeted protein degradation (TPD) based in...

Company Medical Device

Med Vision’s Sleep Disorder Software Receives Category II Approval in China

Fineline Cube Oct 10, 2023

Hangzhou-based Med Vision, a provider of virtual reality (VR)-enabled digital therapeutics (DTx) solutions, has reportedly...

Company Drug

Luye Pharma Files NDA for Paliperidone Palmitate Injectable Suspension with US FDA

Fineline Cube Oct 10, 2023

China-based Luye Pharma Group (HKG: 2186) has announced the submission of a New Drug Application...

Company

Apeloa Pharmaceutical Expands Global Footprint with Apeloa Europe GmbH in Germany

Fineline Cube Oct 10, 2023

China-based contract development and manufacturing organization (CDMO) Apeloa Pharmaceutical Co., Ltd (SHE: 000739) has announced...

Company Deals

AbbVie Acquires Mitokinin, Advancing PINK1 Activator for Parkinson’s Disease

Fineline Cube Oct 10, 2023

AbbVie (NYSE: ABBV) has announced the acquisition of US-based biotechnology company Mitokinin, exercising an exclusive...

Company Drug

Shanghai BDgene’s BD112 Earns Orphan Drug Designation from US FDA for Huntington’s Disease

Fineline Cube Oct 10, 2023

Shanghai BDgene Technology Co., Ltd, a specialist in gene therapy, has announced that its drug...

Company

AstraZeneca Alum Yu Yuping Appointed Vice-President at Merck KGaA’s China Unit

Fineline Cube Oct 10, 2023

Yu Yuping, a seasoned professional with a distinguished career at AstraZeneca (AZ, NASDAQ: AZN), has...

Company Deals

AffaMed Technologies Secures Exclusive Rights to SIFI’s Intraocular Lens Products in Greater China

Fineline Cube Oct 10, 2023

AffaMed Technologies, a joint venture between China’s AffaMed Therapeutics and Italy-based SIFI S.p.A., has announced...

Company Deals

Simcere Pharmaceutical Secures Exclusive Rights to AnDiCon’s Anti-Influenza Candidate ADC189

Fineline Cube Oct 10, 2023

China-based Simcere Pharmaceutical Group (HKG: 2096) has announced a strategic collaboration agreement with domestic firm...

Company Drug

J&J’s Janssen Reports Favorable Spravato Data in Late-Stage TRD Trial

Fineline Cube Oct 10, 2023

Johnson & Johnson’s (J&J; NYSE: JNJ) subsidiary, Janssen, has presented tolerability and efficacy data from...

Company Deals

BMS to Acquire Mirati Therapeutics in a $4.8 Billion Deal

Fineline Cube Oct 10, 2023

Bristol-Myers Squibb (BMS; NYSE: BMY) has entered into a definitive merger agreement with US-based oncology...

Company Deals

Canada’s SGC Partners with HitGen to Enhance Drug Discovery Using DEL Technology

Fineline Cube Oct 9, 2023

The Structural Genomics Consortium (SGC) of Canada has announced a strategic partnership with China-based HitGen...

Company Deals

Adlai Nortye Completes Successful IPO on Nasdaq, Raising $57.5 Million

Fineline Cube Oct 9, 2023

Sino-US biotech Adlai Nortye Ltd (NASDAQ: ANL) successfully completed its initial public offering (IPO) on...

Company Drug

Eli Lilly Launches Three New Oncology Programs Targeting KRAS and Nectin-4

Fineline Cube Oct 9, 2023

Eli Lilly (NYSE: LLY) has announced the initiation of three innovative oncology programs focusing on...

Company Drug

FDA Rejects Eli Lilly’s Application for Lebrikizumab in Atopic Dermatitis Treatment

Fineline Cube Oct 9, 2023

The U.S. Food and Drug Administration (FDA) has rejected Eli Lilly’s (NYSE: LLY) application for...

Company Deals

Bayer Partners with Twist Bioscience for Antibody Discovery in Multiple Disease Areas

Fineline Cube Oct 9, 2023

German pharmaceutical giant Bayer (ETR: BAYN) has entered into a strategic partnership with drug discovery...

Policy / Regulatory

Beijing Launches Comprehensive Plan to Eliminate Cervical Cancer by 2030

Fineline Cube Oct 9, 2023

The Beijing Municipal Health Commission, in collaboration with the Beijing Municipal Medical Insurance Bureau and...

Company Deals

ZhenGe Biotech Partners with Glyco-Therapy to Develop Antibody Drug Conjugate Platform

Fineline Cube Oct 9, 2023

China-based Contract Development and Manufacturing Organization (CDMO) ZhenGe Biotech has announced a strategic partnership with...

Posts pagination

1 … 506 507 508 … 709

Recent updates

  • AstraZeneca Launches Tezspire in China, Bringing First‑In‑Class TSLP Inhibitor Tezepelumab to Severe Asthma and CRSwNP Patients
  • Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA
  • Fosun Pharma Launches Phase 2 Trial of FXS7553 DPP‑1 Inhibitor for COPD in China
  • Asieris Pharmaceuticals Wins FDA Clearance for APL‑2501, an Anti‑CLDN6/9 ADC in Advanced Solid Tumors
  • Hengrui Pharmaceuticals Wins NMPA Clearance for Phase II Trial of HRS‑4729, a Triple‑Agonist Peptide Drug for Type 2 Diabetes
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

AstraZeneca Launches Tezspire in China, Bringing First‑In‑Class TSLP Inhibitor Tezepelumab to Severe Asthma and CRSwNP Patients

Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Company Drug

Fosun Pharma Launches Phase 2 Trial of FXS7553 DPP‑1 Inhibitor for COPD in China

Company Drug

Asieris Pharmaceuticals Wins FDA Clearance for APL‑2501, an Anti‑CLDN6/9 ADC in Advanced Solid Tumors

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.